New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronar... ( PARIS September 2 /- Sanofi-avent...)

HOME >> BIOLOGY >> TECHNOLOGY

New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome

Date:9/2/2007

PARIS, September 2 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH).

The ExTRACT-TIMI 25 and STEEPLE one year results were presented during hotline sessions at the European Society of Cardiology (ESC) Congress in Vienna, Austria.

ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment, Thrombolysis in Myocardial Infarction -- Study 25) trial showed that in patients with STEMI treated with fibrinolysis, at one year, the primary endpoint of death or nonfatal myocardial infarction remained significantly in favor or enoxaparin vs UFH (15.8% vs 17.0% p-0.01). Net clinical benefit (all cause of death / nonfatal MI / nonfatal disabling stroke) was also significantly in favour of enoxaparin vs UFH through one year of follow up (16.0% vs 17.3% p=0.007).

"This was a very large trial with conclusive results at 30 days. The persistence of significant net clinical benefit a full year after treatment is further evidence of the viability of the strategy of using enoxaparin as adjunctive anticoagulant therapy to fibrinolysis in the STEMI patient population," noted ExTRACT TIMI 25 principal investigator Dr. Elliott Antman, M.D., Senior Investigator TIMI Study Group, Director, Samuel A. Levine Cardiac Unit at Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, and lead investigator of the ExTRACT-TIMI 25 study.

ExTRACT TIMI 25 was a major randomized clinical trial that supported the worldwide submission and subsequent approval by the FDA and some European countries of the new Lovenox(R) indication for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).

STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutan
'/>"/>

SOURCE Sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study

Post Your Comments:

(Date:6/19/2013)... Clinverse, Inc. , a global ... today announced it will be exhibiting and showcasing ... Boston, June 24-26, 2013. Clinverse’s eClinical Commerce ... configurable, cloud-based clinical financial lifecycle system. , Clinverse’s ... eClinical Commerce Network, automates site contract set-up and ...

(Date:6/19/2013)... 19, 2013 NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...

(Date:6/19/2013)... India , June 19, ... Bharat Book Bureau presents Innovative ... and Formulation Technology Licensing Opportunities ... http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html ) There ... or controlled release drugs approved ...

(Date:6/19/2013)... 18, 2013 A new look at ... and other trends will highlight technical sessions at ... fall. In its 33rd year, the three-day event is ... of key suppliers, approximately 100 technical presentations and numerous ... international society for optics and photonics , the meeting ...

Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2 NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2 NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3 Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2 Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3 ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2 ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3

[0] Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 [0] NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights [0] Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies [0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology

... (Nasdaq: PRXL ), a leading global ... Ltd, today announced,that it has been recognized ... as,the winner of its Most Innovative Patient ... collaborative efforts of PAREXEL and study,sponsor Glenmark, ...

... AMSTERDAM, October 29 Avantium announced today ... private financing round. Avantium,is active in the ... biofuel and bioplastic, and the improvement of,pharmaceutical ... accelerate its two,proprietary development programs. The focus ...

... Oct. 29 ,Shire plc (LSE: SHP, Nasdaq: SHPGY) the global specialty ... Q3 2008 Financial Highlights, - Product sales up ... up 51% to $444 million - New product sales(1) $276 ... - Total revenues up 28% to $779 million - Non ...

PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy Avantium Completes EUR 18 Million Financing Round Shire's New Product Portfolio Delivers Strong Quarterly Performance

(Date:6/18/2013)... Ph.D., Medical Research Council, Laboratory of Molecular Biology, ... 2013 ICAAC Young Investigator Award. Torrent is being ... the first algorithm to predict antimicrobial regions in ... "we are now applying this algorithm to interrogate ... peptide leads with very appealing results." , ...

(Date:6/18/2013)... MD, June 18, 2013: The Association for Molecular Pathology ... of American Societies for Experimental Biology (FASEB) on July ... membership on June 3, 2013. , The 26 ... and share a common vision for the advancement of ... biomedical and translational research is more important now than ...

(Date:6/18/2013)... refers to a chemical modification of DNA and ... in the DNA sequence. Until now, scientists believed ... of certain genes. Today, a team of researchers ... by Emmanouil Dermitzakis, Louis-Jeantet Professor at the Faculty ... the case and that DNA methylation may play ...

Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2 The secret of DNA methylation 2

[0] The American Society for Microbiology honors Marc Torrent [0] AMP joins the Federation of American Societies for Experimental Biology [0] The secret of DNA methylation

... 2 emissions from using coal are set to double by ... mitigating global climate change. In view of the essential role ... emissions where coal is used. The British Geological ... (NZEC) Phase 1 study in Beijing, China today. The aim of ...

... small amounts of lead in children,s blood -- amounts ... with reduced IQ scores, finds a new six-year Cornell ... on cognitive function in children whose blood-lead levels (BLLs) ... (CDC) standard of 10 micrograms per deciliter (mcg/dl) -- ...

... dengue cause suffering and death around the world. ... and is particularly devastating in children under the age ... these diseases consume vast economic resources in the very ... to controlling these diseases such as insecticides, vaccine development, ...

Cached Biology News:UK scientists lead China closer to carbon capture and storage 2 Even minute levels of lead cause brain damage in children 2 Selfish DNA and the Genetic Control of Vector-Borne Diseases 2 Selfish DNA and the Genetic Control of Vector-Borne Diseases 3

UK scientists lead China closer to carbon capture and storage Even minute levels of lead cause brain damage in children Selfish DNA and the Genetic Control of Vector-Borne Diseases

Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...

... against a partial recombinant IFNA2. Immunogen: ... protein is produced in E. coli. The ... mg. OMIM: 147562, ... MM951100564 MA Code: ABV0P9DPB ...

... Researchers no longer need to perform time consuming ... With Mutation Surveyor, any found variants of the ... clearly indicated in our mutation electropherogram as a ... the bi-directional analysis mode is over 99%, with ...

...

Biology Products:

Mouse Anti-Human QPCT Polyclonal Antibody, Unconjugated from Abnova Corporation Mouse Anti-IFNA2 Monoclonal Antibody, Unconjugated, Clone 1F11 from Abnova Corporation Mutation Surveyor from SoftGenetics, LLC.Finnigan LTQ FT from Thermo Scientific